KR102301753B1 - 아자인돌 화합물, 이의 합성, 및 이의 사용 방법 - Google Patents

아자인돌 화합물, 이의 합성, 및 이의 사용 방법 Download PDF

Info

Publication number
KR102301753B1
KR102301753B1 KR1020167004150A KR20167004150A KR102301753B1 KR 102301753 B1 KR102301753 B1 KR 102301753B1 KR 1020167004150 A KR1020167004150 A KR 1020167004150A KR 20167004150 A KR20167004150 A KR 20167004150A KR 102301753 B1 KR102301753 B1 KR 102301753B1
Authority
KR
South Korea
Prior art keywords
methyl
hydrogen
mmol
added
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167004150A
Other languages
English (en)
Korean (ko)
Other versions
KR20160058757A (ko
Inventor
프라빈 에스. 시루드
마루티 엔. 나익
비카스 나라얀 신디
모하메드 사훌 하메드 피어
모나리자 차테르지
라다 케이. 샌딜
Original Assignee
더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크.
파운데이션 포 니글렉티드 디지즈 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크., 파운데이션 포 니글렉티드 디지즈 리서치 filed Critical 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크.
Publication of KR20160058757A publication Critical patent/KR20160058757A/ko
Application granted granted Critical
Publication of KR102301753B1 publication Critical patent/KR102301753B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020167004150A 2013-07-17 2014-07-10 아자인돌 화합물, 이의 합성, 및 이의 사용 방법 Active KR102301753B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3196/CHE/2013(1) 2013-07-17
IN3196CH2013 2013-07-17
IN3196/CHE/2013(2) 2014-04-30
PCT/US2014/046100 WO2015009525A1 (en) 2013-07-17 2014-07-10 Azaindole compounds, synthesis thereof, and methods of using the same

Publications (2)

Publication Number Publication Date
KR20160058757A KR20160058757A (ko) 2016-05-25
KR102301753B1 true KR102301753B1 (ko) 2021-09-15

Family

ID=51261257

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167004150A Active KR102301753B1 (ko) 2013-07-17 2014-07-10 아자인돌 화합물, 이의 합성, 및 이의 사용 방법

Country Status (10)

Country Link
US (1) US9163020B2 (enExample)
EP (1) EP3021947B1 (enExample)
JP (1) JP6366709B2 (enExample)
KR (1) KR102301753B1 (enExample)
CN (1) CN105636646B (enExample)
AU (1) AU2014290598B2 (enExample)
CA (1) CA2918487C (enExample)
EA (1) EA028611B1 (enExample)
ES (1) ES2644025T3 (enExample)
WO (1) WO2015009525A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US11173113B2 (en) 2017-12-06 2021-11-16 Prollergy Corporation Composition and method for reducing allergic response
RU2702224C2 (ru) * 2018-03-29 2019-10-07 Общество С Ограниченной Ответственностью "Мт-Медикалс" Производные фенил формамидина, обладающие антимикобактериальной активностью
WO2019239382A1 (en) 2018-06-15 2019-12-19 Cadila Healthcare Limited Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria
WO2020188405A1 (en) * 2019-03-20 2020-09-24 Foundation For Neglected Disease Research Benzimidazoles derivatives as anti-tuberculosis agents
CN111393435A (zh) * 2020-03-16 2020-07-10 青岛吉澳医药科技有限公司 氮杂吲哚酰胺类化合物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113606A1 (en) 2010-03-18 2011-09-22 Institut Pasteur Korea Anti-infective compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
UA99729C2 (en) * 2007-08-10 2012-09-25 Х. Луннбек А/С Heteroaryl amide analogues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113606A1 (en) 2010-03-18 2011-09-22 Institut Pasteur Korea Anti-infective compounds

Also Published As

Publication number Publication date
CN105636646B (zh) 2017-12-19
WO2015009525A1 (en) 2015-01-22
CA2918487A1 (en) 2015-01-22
EP3021947B1 (en) 2017-08-23
CN105636646A (zh) 2016-06-01
BR112016000712A2 (pt) 2022-03-22
US20150025087A1 (en) 2015-01-22
AU2014290598A1 (en) 2016-02-11
EA201690227A1 (ru) 2016-07-29
ES2644025T3 (es) 2017-11-27
JP2016530242A (ja) 2016-09-29
JP6366709B2 (ja) 2018-08-01
EA028611B1 (ru) 2017-12-29
KR20160058757A (ko) 2016-05-25
EP3021947A1 (en) 2016-05-25
AU2014290598B2 (en) 2018-11-08
CA2918487C (en) 2021-08-03
US9163020B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
KR102301753B1 (ko) 아자인돌 화합물, 이의 합성, 및 이의 사용 방법
EP3353179B1 (en) Heterocyclic compounds and uses thereof
CN108473499B (zh) 新颖的吡唑并嘧啶衍生物
Sriram et al. Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives
US10822339B2 (en) Pyrrolopyrimidine five-membered azacyclic derivative and application thereof
CA2921568A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
US9284325B2 (en) Spectinamides as anti-tuberculosis agents
CN113498340A (zh) 用于治疗皮肤疾病噻吩基苯胺化合物
EP3819299A1 (en) Hypoxanthine compound
TW202200573A (zh) 噁唑啶酮化合物及其做為抗菌劑之使用方法
CN111479805B (zh) 治疗性吲唑
EP3250205B1 (en) Benzimidazole sulfide derivatives for the treatment or prevention of tuberculosis
EP3148518B1 (en) Novel compounds as anti-tubercular agents
BR112016000712B1 (pt) Compostos de azaindol, síntese dos mesmos e métodos de uso dos mesmos
HK1254606B (zh) 手性二芳基大环及其用途
HK1171388A (en) Spectinamides as anti-tuberculosis agents
HK1171388B (en) Spectinamides as anti-tuberculosis agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190529

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201204

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210610

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210908

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210909

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240729

Start annual number: 4

End annual number: 4